Non-small cell lung cancer (NSCLC) is a heterogeneous group of malignancies
including squamous cell carcinoma, adenocarcinoma, bronchioloalveolar carcinoma
and large cell carcinoma. They are known to be of poor prognosis, despite a
better understanding of bronchial oncogenesis. This descriptive retrospective
study carried out over three years (January 2013 to December 31st,
2016) at the Oncology Department of the Treichville University Hospital in
Abidjan was aimed to assess the efficacy of new treatments for NSCLC in Cote d’Ivoire
and to specify their benefit in terms of quality of life, comfort and overall
survival. This 77 patients study, found that NSCLC, the most frequent of which
is squamous cell carcinoma, occurs in relatively young subjects, smokers (91%)
diagnosed at a locally advanced or metastatic stage (89%). Cisplatin base multi-drug
chemotherapy was mostly used (71%). Combined all treatments, there was a significant
clinical gain. However, no complete response was observed. Hematological and
digestive toxicities were seen in more than 30% of cases. Overall survival was
of 9 months on average. This study is an advocate to optimize primary
prevention policies for a cancer with poor prognosis despite the development of
new treatments such as target therapies.
References
[1]
Travis, W.D., et al. (1999) Histological Classification of Lung and Pleural Tumours. Histological Typing of Lung and Pleural Tumours, 3, 21-24.
https://doi.org/10.1007/978-3-642-60049-4_2
[2]
Pelletier, M.P., De B. Edwardes, M.D., Michel, R.P., Halwani, F. and Morin, J.E. (2001) Prognostic Markers in Resectable Non-Small Cell Lung Cancer: A Multivariate Analysis. Canadian Journal of Surgery, 44,180-188.
[3]
Niang, A., Bonnichon, A., Ba-Fall, K., Dussart, C., Camara, P., Vaylet, F., Mbaye, P.S., L’Her, P., Sane, M. and Margery, J. (2001) Le cancer bronchique au Sénégal. MedecineTropicale, 67, 651-656.
[4]
Ladanyi, M. and Pao, W. (2008) Lung Adenocarcinoma: Guiding EGFR-Targeted Therapy and Beyond. Modern Pathology, 21, 16-22.
https://doi.org/10.1038/modpathol.3801018
[5]
Culier, J.P.S., et al. (2008) Diagnostic the New TNM Classification for Lung Cancer. Revue des Maladies Respiratoires, 25, 3S40-3S47.
[6]
Duffaud, F. and Therasse, P. (2000) Nouvelles recommandations pour l’évaluation de la réponse tumorale dans les tumeurs solides. Bull du cancer, 12, 881-886.
[7]
Kaplan, E.L. and Meier, P. (1958) Non Parametric Estimation from Incomplete Observations. American Statistical Association, 53, 457-481.
http://www.jstor.org/stable/2281868
[8]
Ba, I., et al. (2014) Recensement général de la population et de l’habitat en Cote d’Ivoire: Rapport d’exécution et de présentation des principaux résultats. RGPH, 4, 1-49.
[9]
Doll, R., Peto, R., et al. (1978) Cigarette Smoking and Bronchial Carcinoma: Dose and Time Relationships among Regular Smokers and Lifelong Non-Smokers. J Epidemiology & Community Health, 32, 303-313.
https://doi.org/10.1136/jech.32.4.303
[10]
Wynder, E. and Graham, E.A. (1950) Tobacco Smoking as a Possible Etiologic Factor in Bronchiogenic Carcinoma. A Study of Six Hundred and Eighty-Four Proved Cases. JAMA, 143, 329-346.
https://doi.org/10.1001/jama.1950.02910390001001
[11]
Doll, R. and Hill, A.B. (1952) A Study of the Aetiology of Carcinoma of Lung. British Medical Journal, 2, 1271-1286. https://doi.org/10.1136/bmj.2.4797.1271
[12]
Al Kattan, K. and Goldstraw, P. (1995) Completion Pneumonectomy: Indications and Outcome. The Journal of Thoracic and Cardiovascular Surgery, 110, 1125-1129.
https://doi.org/10.1016/S0022-5223(05)80182-5
[13]
Donnadieu, N., Paesmans, M. and Sculier, J.P. (1991) Chimiothérapie des cancers bronchiques non à petites cellules: Meta-analyse de la littérature en fonction de l’extension de la maladie. Revue des maladies respiratoires, 8, 197-204.
[14]
Scagliotti, G.V., Parikh, P., Von Pawel, J., et al. (2008) Phase III Study Comparing Cisplatin plus Gemcitabine with Cisplatin plus Premetrexed in Chemotherapy-Naive Patients with Advanced Stage Non-Small-Cell Jung Cancer. Journal of Clinical Oncology, 26, 3543-3551. https://doi.org/10.1200/JCO.2007.15.0375
[15]
Edward, S.K., Ann, M.M., William, N.W., et al. (2009) A Phase 2 Study of Cetuximab in Combination with Docetaxel in Chemotherapy-Refractory/Resistant Patients with Advanced Nonsmall Cell Lung Cancer. Cancer, 115, 1713-1722.
https://doi.org/10.1002/cncr.24148
[16]
Johnson, D.H., Fehrenbacher, L., Novotny, W.F., et al. (2004) Randomized Phase II Trial Comparing Bevacizumab plus Cisplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 22, 2184-2191. https://doi.org/10.1200/JCO.2004.11.022
[17]
El Ouazzani, H., Menchafou, I., Achachi, L., El Ftouh, M. and El Fassy Fihry, M.T. (2010) Delay in the Diagnosis of Primary Bronchial Cancer. Study Carried out in the Pneumology Unit of Ibn Sina University Hospital, Rabat (Morocco). Revue de Pneumologie Clinique, 66, 335-341. https://doi.org/10.1016/j.pneumo.2010.02.004
[18]
Pérol, M. and Pérol, D. (2004) The Role of Meta-Analysis in Assessing the Treatment of Advanced Non-Small Cell Lung Cancer. Revue de Pneumologie Clinique, 60, 29-37. https://doi.org/10.1016/S0761-8417(04)72080-5
[19]
Blanchon, F., Grivaux, M., Zureik, M., et al. (2006) CohorteKbp-2000-Cphg: Evaluation des facteurs pronostiques de la survie du cancer bronchique primitif à 2 et 5 ans. Revue des Maladies Respiratoires, 23, 165-171.
https://doi.org/10.1016/S0761-8425(06)71482-6
